How does Rosuvastatin compare to PCSK9 inhibitors in treating severe dyslipidemia, and what are the advantages and limitations of each therapy?
Sahil KapoorExplorer
Sign Up to our social questions and Answers Engine to ask questions, answer people’s questions, and connect with other people.
Please briefly explain why you feel this question should be reported.
Please briefly explain why you feel this answer should be reported.
Please briefly explain why you feel this user should be reported.
Rosuvastatin, a statin, effectively lowers LDL cholesterol by inhibiting HMG-CoA reductase. PCSK9 inhibitors, like alirocumab, enhance LDL receptor recycling, further reducing LDL. Statins are oral, cost-effective, and widely used, but may cause muscle pain. PCSK9 inhibitors, administered via injection, are more potent but significantly more expensive and primarily used when statins are insufficient or unsuitable.